Tokyo Tape
Sign in
← Nipro

Quarterly report · Q1

8086.TEDINET S100OZ7P
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥127.9bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥494.8bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥118.0bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.0bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥5.5bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥7.3bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥27.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.2bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥9.0bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥5.3bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥5.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.3bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥5.7bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥3.5bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥947.6bnat 2022-06-30Cons.Assets
Total assets¥930.3bnat 2022-03-31Cons.Assets
Total assets¥874.8bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥730.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥730.5bnat 2022-03-31Cons.Liabilities
Net assets / equity¥217.3bnat 2022-06-30Cons.Net assets
Net assets / equity¥199.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥185.9bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥84.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥95.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥32.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥20.242021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥28.662022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
Equity ratio21.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio19.8%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥154m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥855m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥211m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥7.1bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥99.3bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥97.7bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥23.2bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥17.9bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥5.3bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥407m
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-06-30¥13.7bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-06-30¥12.2bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.0bn
—segment totalrevenue2022-04-01 → 2022-06-30¥136.2bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥127.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥8.4bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥137.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥127.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥9.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥10.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥693m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥153m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥540m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30¥145m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥8.8bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥8.8bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥5.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2021-04-01 → 2021-06-30¥92.2bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2021-04-01 → 2021-06-30¥90.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.5bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2021-04-01 → 2021-06-30¥9.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2021-04-01 → 2021-06-30¥21.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2021-04-01 → 2021-06-30¥16.4bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2021-04-01 → 2021-06-30¥587m
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2021-04-01 → 2021-06-30¥12.4bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2021-04-01 → 2021-06-30¥10.8bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2021-04-01 → 2021-06-30¥844m
—segment totalrevenue2021-04-01 → 2021-06-30¥126.1bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥117.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥8.2bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥10.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥126.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥118.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥8.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥11.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 442
ItemContextValueUnit
Liabilities and net assetsCurrentQuarterInstant947561000000JPY
Net salesPrior1YTDDuration118001000000JPY
Net salesCurrentYTDDuration127892000000JPY
Cost of salesPrior1YTDDuration81791000000JPY
Cost of salesCurrentYTDDuration88685000000JPY
Gross profitPrior1YTDDuration36209000000JPY
Gross profitCurrentYTDDuration39206000000JPY
Selling general and administrative expensesPrior1YTDDuration30692000000JPY
Selling general and administrative expensesCurrentYTDDuration36252000000JPY
Operating incomePrior1YTDDuration5517000000JPY
Operating incomeCurrentYTDDuration2954000000JPY
Interest income noiPrior1YTDDuration243000000JPY
Interest income noiCurrentYTDDuration248000000JPY
Dividends income noiPrior1YTDDuration48000000JPY
Dividends income noiCurrentYTDDuration59000000JPY
Foreign exchange gains noiPrior1YTDDuration471000000JPY
Foreign exchange gains noiCurrentYTDDuration5070000000JPY
Other noiPrior1YTDDuration468000000JPY
Other noiCurrentYTDDuration628000000JPY
Non operating incomePrior1YTDDuration1232000000JPY
Non operating incomeCurrentYTDDuration6007000000JPY
Interest expenses noePrior1YTDDuration1022000000JPY
Interest expenses noeCurrentYTDDuration1011000000JPY
Equity in losses of affiliates noePrior1YTDDuration208000000JPY
Equity in losses of affiliates noeCurrentYTDDuration274000000JPY
Other noePrior1YTDDuration287000000JPY
Other noeCurrentYTDDuration338000000JPY
Non operating expensesPrior1YTDDuration1518000000JPY
Non operating expensesCurrentYTDDuration1624000000JPY
Ordinary incomePrior1YTDDuration5231000000JPY
Ordinary incomeCurrentYTDDuration7337000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration343000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration1909000000JPY
Gain on sales of investment securities eiPrior1YTDDuration109000000JPY
Gain on sales of investment securities eiCurrentYTDDuration39000000JPY
Other eiPrior1YTDDuration0JPY
Other eiCurrentYTDDuration0JPY
Extraordinary incomePrior1YTDDuration453000000JPY
Extraordinary incomeCurrentYTDDuration1949000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration74000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration30000000JPY
Provision of allowance for doubtful accounts elPrior1YTDDuration150000000JPY
Provision of allowance for doubtful accounts elCurrentYTDDuration40000000JPY
Expense for treatment of waste elPrior1YTDDuration34000000JPY
Expense for treatment of waste elCurrentYTDDuration70000000JPY
Dispute costs elPrior1YTDDuration100000000JPY
Dispute costs elCurrentYTDDuration118000000JPY
Other elPrior1YTDDuration36000000JPY
Other elCurrentYTDDuration18000000JPY
Extraordinary lossPrior1YTDDuration395000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass